{"name":"Qing XIe","slug":"qing-xie","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Direct-acting antiviral agents","genericName":"Direct-acting antiviral agents","slug":"direct-acting-antiviral-agents","indication":"Hepatitis C","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Peginterferon α-2b based treatment group","genericName":"Peginterferon α-2b based treatment group","slug":"peginterferon-2b-based-treatment-group","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Direct-acting antiviral agents","genericName":"Direct-acting antiviral agents","slug":"direct-acting-antiviral-agents","phase":"phase_2","mechanism":"Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins.","indications":["Hepatitis C","Hepatitis B"],"catalyst":""},{"name":"Peginterferon α-2b based treatment group","genericName":"Peginterferon α-2b based treatment group","slug":"peginterferon-2b-based-treatment-group","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9lNi1hRVlsVzNDRmFHZHVYbVQwc05PcTBUSElfbFloYnlzWm9XVEpvTkJReldIRGtsQkpka2tHQlBNSkk1aUExVG4tNUpxakhxMTB3?oc=5","date":"2025-07-18","type":"deal","source":"36 Kr","summary":"$7 Billion Deal: 30-Year-Old 'Fourth-Generation Scion of a Wealthy Family' Acquires Shanghai Innovative Pharmaceutical Company - 36 Kr","headline":"$7 Billion Deal: 30-Year-Old 'Fourth-Generation Scion of a Wealthy Family' Acquires Shanghai Innovative Pharmaceutical C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE96U0pNLW1EVEMzWkVWTFl0aGpSWFJ2WVh5M29GVTB6aGhyTVVRa2ZjLTVNZ25DNDZ3amxCOVBzMWhaSnA0eENMbUhTUGpyemR5WFNUVV9lVkdrdGp2T3lJ?oc=5","date":"2025-03-10","type":"pipeline","source":"Nature","summary":"Accelerating discovery of bioactive ligands with pharmacophore-informed generative models - Nature","headline":"Accelerating discovery of bioactive ligands with pharmacophore-informed generative models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPLVVCRENNeXF1WWoxTGZKVkxlQnJLMG14OHdYLXduMk1DSzAxcmYzcFZPMDg5Zy1XM0ItMk5pZkdHWUJESm5CR1hJNUxWbU9Gd3hldGZSWHI2b3c3eVk4Q2NjbmNmcDBhQnpTa2RFMVZzdDhiX3RjQWRLaTZhRHh6UXpkNXVxcVZCOXhnZjMzX2dnOEU0?oc=5","date":"2024-11-08","type":"pipeline","source":"Times Higher Education","summary":"Global Undergraduate Awards: 2024 winners - Times Higher Education","headline":"Global Undergraduate Awards: 2024 winners","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}